IFM Investors Pty Ltd Purchases New Shares in Charles River Laboratories International, Inc. (NYSE:CRL)

IFM Investors Pty Ltd acquired a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm acquired 9,586 shares of the medical research company’s stock, valued at approximately $2,597,000.

Other hedge funds have also recently bought and sold shares of the company. First Trust Direct Indexing L.P. purchased a new position in Charles River Laboratories International during the first quarter worth about $211,000. Norden Group LLC boosted its stake in shares of Charles River Laboratories International by 2,642.3% in the 1st quarter. Norden Group LLC now owns 31,399 shares of the medical research company’s stock worth $8,508,000 after buying an additional 30,254 shares during the last quarter. Woodmont Investment Counsel LLC purchased a new position in shares of Charles River Laboratories International in the 1st quarter worth approximately $218,000. Congress Wealth Management LLC DE grew its holdings in shares of Charles River Laboratories International by 0.9% in the first quarter. Congress Wealth Management LLC DE now owns 54,316 shares of the medical research company’s stock valued at $14,717,000 after acquiring an additional 500 shares in the last quarter. Finally, Dumont & Blake Investment Advisors LLC increased its position in shares of Charles River Laboratories International by 1.4% during the first quarter. Dumont & Blake Investment Advisors LLC now owns 4,415 shares of the medical research company’s stock valued at $1,196,000 after acquiring an additional 62 shares during the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Shannon M. Parisotto sold 5,882 shares of the company’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the transaction, the executive vice president now owns 2,596 shares of the company’s stock, valued at $626,155.20. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, EVP Shannon M. Parisotto sold 5,882 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the sale, the executive vice president now owns 2,596 shares in the company, valued at approximately $626,155.20. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP William D. Barbo sold 4,050 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the completion of the transaction, the vice president now owns 22,879 shares in the company, valued at $5,685,431.50. The disclosure for this sale can be found here. Insiders sold a total of 14,932 shares of company stock valued at $3,693,663 in the last three months. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Price Performance

NYSE CRL traded up $1.22 during trading hours on Friday, hitting $229.03. The company had a trading volume of 322,127 shares, compared to its average volume of 486,257. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.16 and a current ratio of 1.52. The firm has a market capitalization of $11.80 billion, a price-to-earnings ratio of 24.87, a PEG ratio of 1.78 and a beta of 1.40. Charles River Laboratories International, Inc. has a 52 week low of $161.65 and a 52 week high of $275.00. The firm has a 50 day simple moving average of $253.48 and a 200 day simple moving average of $222.64.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.39 by $0.07. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $991.25 million. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The company’s revenue for the quarter was down 7.9% on a year-over-year basis. During the same period in the prior year, the firm posted $2.98 earnings per share. Equities research analysts expect that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on CRL. UBS Group boosted their price target on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the stock a “buy” rating in a report on Thursday, February 15th. Argus increased their target price on shares of Charles River Laboratories International from $240.00 to $290.00 and gave the company a “buy” rating in a research report on Monday, March 18th. Robert W. Baird lifted their price target on shares of Charles River Laboratories International from $252.00 to $268.00 and gave the stock an “outperform” rating in a report on Thursday, February 15th. Evercore ISI increased their price objective on Charles River Laboratories International from $260.00 to $265.00 and gave the company an “outperform” rating in a report on Thursday, February 15th. Finally, Guggenheim downgraded Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, Charles River Laboratories International presently has an average rating of “Moderate Buy” and an average target price of $253.23.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).